Ozenoxacin

Products

Ozenoxacin was approved in the United States in 2017 as a cream (Xepi).

Structure and properties

Ozenoxacin (C21H21N3O3, Mr = 363.4 g/mol) exists as a white to slightly yellow powder. Unlike most quinolones, it is not fluorinated. Ozenoxacin carries a pyridinyl group at position C-7.

Effects

Ozenoxacin has bactericidal properties and is effective against and including MRSA. The effects are due to inhibition of bacterial DNA replication by inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV.

Indications

For the treatment of impetigo caused by or .

Dosage

According to the professional information. The cream is applied thinly twice daily for five days.

Contraindications

Ozenoxacin is contraindicated in case of hypersensitivity. For complete precautions, see the drug label.

Adverse Effects

Very rarely, seborrheic dermatitis and rosacea have been observed as adverse effects.